Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
1-A
1-A POS
1-A-W
1-A/A
1-K
1-K/A
1-SA
1-SA/A
1-U
1-U/A
1-Z
1-Z-W
1-Z/A
1/A
10-12B
10-12B/A
10-12G
10-12G/A
10-D
10-D/A
10-K
10-K/A
10-K405
10-K405/A
10-KT
10-KT/A
10-Q
10-Q/A
10-QSB
10-QSB/A
10-QT
10-QT/A
10KSB
11-K
11-K/A
11-KT
13F-HR
13F-HR/A
13F-NT
13F-NT/A
13FCONP
144
144/A
15-12B
15-12B/A
15-12G
15-12G/A
15-15D
15-15D/A
15F-12B
15F-12G
15F-12G/A
15F-15D
18-K
18-K/A
19B-4E
2-E
20-F
20-F/A
20FR12B
20FR12B/A
20FR12G/A
24F-2NT
24F-2NT/A
25
25-NSE
25-NSE/A
25/A
253G1
253G2
253G3
3
3/A
305B2
305B2/A
4
4/A
40-17F1
40-17F1/A
40-17F2
40-17F2/A
40-17G
40-17G/A
40-202A
40-202A/A
40-206A
40-24B2
40-33
40-6B
40-6B/A
40-6C
40-6C/A
40-8B25
40-8F-2/A
40-APP
40-APP/A
40-F
40-F/A
40-OIP
40-OIP/A
40FR12B
40FR12B/A
424B1
424B2
424B3
424B4
424B5
424B7
424B8
424H
424H/A
425
485APOS
485B24E
485BPOS
485BXT
486APOS
486BPOS
486BXT
487
497
497AD
497J
497K
5
5/A
6-K
6-K/A
8-A12B
8-A12B/A
8-A12G
8-A12G/A
8-K
8-K/A
8-K12B
8-K12B/A
8-K12G3
8-K12G3/A
8-K15D5
8-K15D5/A
8-M
9-M
ABS-15G
ABS-15G/A
ABS-EE
ABS-EE/A
ADV-E
ADV-H-C
ADV-H-T
ADV-NR
ANNLRPT
APP NTC
APP ORDR
APP WD
APP WD/A
ARS
ARS/A
ATS-N
ATS-N/CA
ATS-N/MA
ATS-N/UA
AW
AW WD
C
C-AR
C-AR-W
C-AR/A
C-TR
C-U
C-U-W
C-W
C/A
C/A-W
CB
CB/A
CERT
CERTARCA
CERTBATS
CERTCBO
CERTNAS
CERTNYS
CERTPAC
CFPORTAL
CFPORTAL/A
CORRESP
CT ORDER
D
D/A
DEF 14A
DEF 14C
DEF13E3
DEF13E3/A
DEFA14A
DEFA14C
DEFC14A
DEFC14A
DEFC14C
DEFM14A
DEFM14C
DEFN14A
DEFR14A
DEFR14C
DEFS14A
DEFS14C
DEL AM
DFAN14A
DFRN14A
DOS/A
DSTRBRPT
DSTRBRPT/A
EFFECT
F-1
F-1/A
F-10
F-10/A
F-10EF
F-1MEF
F-3
F-3/A
F-3ASR
F-3D
F-4
F-4/A
F-6
F-6 POS
F-6/A
F-6EF
F-7
F-8 POS
F-80
F-N
F-X
F-X/A
FOCUSN
FOCUSN/A
FWP
G-405
G-FIN/A
IRANNOTICE
MA
MA-A
MA-I
MA-I/A
MA-W
MA/A
MSD
MSD/A
N-14
N-14 8C
N-14 8C/A
N-14/A
N-14MEF
N-18F1
N-1A
N-1A/A
N-2
N-2/A
N-23C-2
N-23C3A
N-23C3B
N-2MEF
N-30B-2
N-30D
N-30D/A
N-4
N-4/A
N-54A
N-54C
N-6
N-6/A
N-6F
N-8A
N-8A/A
N-8B-2/A
N-8F
N-8F NTC
N-8F ORDR
N-8F/A
N-CEN
N-CEN/A
N-CSR
N-CSR/A
N-CSRS
N-CSRS/A
N-MFP2
N-MFP2/A
N-PX
N-PX/A
N-Q
N-Q/A
NO ACT
NPORT-P
NPORT-P/A
NRSRO-CE
NRSRO-CE/A
NRSRO-UPD
NSAR-A
NSAR-A/A
NSAR-AT
NSAR-B
NSAR-B/A
NSAR-BT
NSAR-U
NSAR-U/A
NT 10-K
NT 10-K/A
NT 10-Q
NT 10-Q/A
NT 11-K
NT 20-F
NT 20-F/A
NT N-CEN
NT N-MFP2
NT NPORT-EX
NT-NCSR
NT-NCSR/A
NT-NSAR
NT-NSAR/A
NTFNCSR
NTN 10Q
POS 8C
POS AM
POS AMI
POS EX
POS462B
POSASR
PRE 14A
PRE 14C
PREC14A
PREC14C
PREM14A
PREM14C
PREN14A
PRER14A
PRER14C
PRRN14A
PX14A6G
QRTLYRPT
QUALIF
REG-NR
REGDEX
REGDEX/A
REVOKED
RW
RW WD
S-1
S-1/A
S-11
S-11/A
S-11MEF
S-1MEF
S-1MEF
S-3
S-3/A
S-3ASR
S-3D
S-3DPOS
S-3MEF
S-4
S-4 POS
S-4/A
S-4MEF
S-6
S-6/A
S-8
S-8 POS
S-B
S-B/A
SC 13D
SC 13D/A
SC 13E
SC 13E/A
SC 13E1
SC 13E1/A
SC 13E3
SC 13E3/A
SC 13E4
SC 13E4/A
SC 13G
SC 13G/A
SC 14D9
SC 14D9/A
SC 14F1
SC TO-C
SC TO-I
SC TO-I/A
SC TO-T
SC TO-T/A
SC14D9C
SD
SD/A
SDR/A
SE
SEC STAFF
SEC STAFF ACTION
SEC STAFF LETTER
SF-1/A
SF-3
SF-3/A
SUPPL
T-3
T-3/A
TA-1
TA-1/A
TA-2
TA-2/A
TA-W
UPLOAD
WDL-REQ
X-17A-5
X-17A-5/A
Tags
Inv. presentation
Quarterly results
Tarsus Pharmaceuticals, Inc.
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
08/10/2023
8-K
Quarterly results
Docs:
"
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements XDEMVY™ 0.25% received FDA approval for the treatment for Demodex blepharitis
"
05/09/2023
8-K
Quarterly results
Docs:
"
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA
"
11/08/2022
8-K
Quarterly results
Docs:
"
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements New Drug Application for TP-03 accepted; PDUFA target action date August 25, 2023
"
08/11/2022
8-K
Quarterly results
Docs:
"
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; NDA submission expected this year
"
05/10/2022
8-K
Quarterly results
11/09/2021
8-K
Quarterly results
Docs:
"
Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements On track to complete enrollment in the fourth quarter of 2021 for the Saturn-2 Phase 3, the second pivotal trial of TP-03 for the treatment of Demodex blepharitis; topline data expected in the first quarter of 2022
"
08/04/2021
8-K
Quarterly results
Docs:
"
Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis; results presented at the 2021 American Society of Cataract and Refractive Surgery conference
"
05/11/2021
8-K
Quarterly results
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy